Zydus Lifesciences will roll out generic semaglutide injections in India post-patent expiry, using a reusable single-pen ...

Zydus to launch Semaglutide Injection in India, featuring a unique reusable pen for improved diabetes and obesity management.

Zydus Lifesciences will launch generic versions of semaglutide injections for obesity and diabetes in India after patent expiry of the Ozempic active ingredient in late March, it said on Wednesday.

This injection reduces the production of angiotensin, a hormone that increases blood pressure, in the body.

Patent protection for semaglutide, the active ingredient in Danish drugmaker Novo Nordisk's diabetes drug Ozempic and ...

One of the standout features of Zydus' semaglutide offering is its unique, indigenously developed drug delivery system ...

Zydus plans to launch its diabetes and obesity injection using a reusable adjustable pen device after patent expiry, as more Indian drugmakers enter the market.

Ahmedabad: Zydus Lifesciences Limited said it plans to launch semaglutide injection in India under the brand names Semaglyn, Mashema and Alterme after.